Search
Sulfasalazine
go.drugbank.com/drugs/DB00795ApprovedInvestigationalSulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. … [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970.
Categories: Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)Ansuvimab
go.drugbank.com/drugs/DB16385Approved[A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD. … ™ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials.
Categories: Amino Acids, Peptides, and Proteins, Immune Sera and ImmunoglobulinsFlavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on … [A274616,L54226] FMN is composed of an isoalloxazine ring - which serves as the active redox center - attached to a ribityl phosphate chain.
Mixtures: Supravite 10ml Ampoule, Soluvit NCategories: Enzymes and Coenzymes, Nucleic Acids, Nucleotides, and NucleosidesDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. … [L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and
Categories: Amino Acids, Peptides, and Proteins, Skin and Mucous Membrane AgentsCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Categories: tixagevimab and cilgavimab, Amino Acids, Peptides, and ProteinsVO659
go.drugbank.com/drugs/DB18160InvestigationalVO659 is an antisense oligonucleotide being investigated for the treatment of Huntington's disease.
Synonyms: an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)Cefoperazone
go.drugbank.com/drugs/DB01329ApprovedInvestigationalWithdrawnIt is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis … , skin infections, endometritis, and bacterial septicemia.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020. … and BioNTech.
Categories: Amino Acids, Peptides, and ProteinsLincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approved[A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains … [A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214]
Categories: Macrolides, Lincosamides and StreptograminsPlazomicin
go.drugbank.com/drugs/DB12615ApprovedIt mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. … However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations [A33942